Sometimes, the best moves a team makes are the ones they don't make. That's the lesson the baseball world is learning again as Carlos Correa's ankle—the same one that famously derailed megadeals with the Mets and Giants four years ago—has finally given out.

On Wednesday, the Houston Astros announced that their star shortstop will miss the remainder of the 2026 season after suffering a torn tendon in his left ankle during batting practice. Correa felt a "pop" while taking swings before a game against the Los Angeles Dodgers, and imaging revealed the extent of the damage. He's now facing surgery and a recovery timeline of six to eight months.

For the Astros, this is a gut punch. Correa was hitting .279 with three home runs and 16 RBIs this season, anchoring a lineup that now has a significant hole to fill. But for fans of the Mets and Giants, this feels like a moment of vindication—even if it's bittersweet.

Let's rewind to the 2022-23 MLB offseason, when Correa was the prize of free agency. Both the San Francisco Giants and New York Mets were ready to hand him contracts worth around $300 million. Then came the physicals. Both teams flagged concerns about his left ankle, and the deals collapsed. At the time, the decision was widely criticized. Fans and analysts alike questioned whether the teams were being too cautious with a generational talent.

Fast forward four years, and that caution looks prescient. The same ankle that raised red flags now requires season-ending surgery. The narrative has flipped completely.

Correa eventually signed with the Minnesota Twins for six years and $200 million—a massive deal, but one that paled in comparison to what the Mets and Giants had offered. This past offseason, the Twins traded him to Houston, sending $33 million in cash along with him to cover the remaining $104 million on his contract.

Now, as Correa faces a long recovery, the baseball world is reminded that sometimes the most important skill in the front office isn't signing the star—it's knowing when to walk away.